Rapid, Reliable Diagnostic and PoC Tests Are Requisite for “Test to Treat"
Progress in rapid diagnostic and point-of-care testing propelled by the pandemic can improve timeliness and precision of anti-infective treatment.
Paxlovid Prescribing by Pharmacists: A New Paradigm
The Paxlovid approval reaffirms the importance of pharmacists in fighting COVID-19.
Risk of Blood Clots Remains for Nearly a Year After COVID-19 Infection
In 2020 alone, the COVID-19 pandemic may have caused an additional 10500 heart attacks, strokes, and other blood clot complications across England and Wales.
Gut Microbiota in Early Life May Affect Vaccine Efficacy
Bifidobacterium and Bacteroides in the gut microbiome are important to vaccine responsiveness and could be used in vaccine adjuvants in the future, a recent review shows.
European Union Authorizes Novavax Booster
The vaccine is available in adults 18 years and older.
“Massive Global Failures” of COVID-19 Response Caused Millions of Preventable Deaths
The Lancet Commission called for global cooperation to end the continued spread of COVID-19 and effectively prevent future pandemics.
Rebound of COVID-19 After Treatment With Paxlovid
COVID-19 viral load rebound occurred in 2.3% of nirmatrelvir–ritonavir (Paxlovid) recipients and in 1.7% of placebo recipients.
Greater Mortality and Disease Severity in Patients with Hepatitis B and COVID-19
A meta-analysis study shows having the comorbidity presents significant health risks for this patient population.
Can Zoonotic Exposure Predict COVID-19 Prevalence?
Investigators surmise a natural bat exposure within certain areas of the world may correspond with lower COVID-19 incidence rates.
Mucosal Antibody Response to COVID-19 mRNA Vaccines Depends on Prior Infection
Injected COVID-19 mRNA vaccines alone were ineffective at producing mucosal antibody responses, according to a recent study that suggested seeking new strategies such as intranasal vaccines.
Risk of Severe COVID-19 with BA.1 and BA.2 Subvariants Low
COVID-19 disease severity was mild in individuals in Qatar infected with the Omicron BA.1 and BA.2 sublineages with vaccination and booster doses reducing risks even further, a new study showed.
Valneva Publishes Trial Results for Inactivated, Whole-Virus COVID-19 Vaccine
Valneva’s COVID-19 vaccine candidate, VLA2001, demonstrated superior virus-neutralizing antibodies compared to the AstraZeneca vaccine.
Oral Antivirals Can Benefit Hospitalized COVID-19 Patients
"Real-world" population study finds the oral antivirals authorized for non-hospitalized COVID-19 patients can benefit when started in the hospital.
Infectious Diseases Update: September 3, 2022
Catch up on all the important news and clinical care topics you may have missed this week.
CDC Recommends mRNA Boosters
The federal agency's recommendation for both the Moderna and the Pfizer-BioNTech updated bivalent vaccines allows people to get the booster dose this fall.
FDA Authorizes mRNA Bivalent COVID-19 Vaccines as Boosters
This Emergency Use Authorization for the Moderna and Pfizer-BioNTech vaccines brings them both one step closer for people to become eligible for these boosters.
Authorized During Delta, Paxlovid Demonstrates Effectiveness Against Omicron
Oral antiviral nirmatrelvir/ritonavir is shown to be effective treatment for seniors against Omicron.
AIVITA Publishes Phase 1 and 2 Trial Results of Novel COVID-19 Vaccine
AIVITA’s COVID-19 vaccine candidate contains only the subject’s primed immune cells.
Thromboembolism After COVID-19 vs. Influenza
A new study found that patients hospitalized with COVID-19 are at significantly higher risk for venous thromboembolism in the ensuing 3 months than are patients hospitalized with influenza.
Risk of Myocarditis Higher After COVID-19 Infection Than After Vaccination
A study published this week by the American Heart Association found myocarditis was more common after COVID-19 infection than after COVID-19 vaccination.
Moderna Sues Pfizer-BioNTech Over mRNA Technology Infringement
The Cambridge-MA., company accuses Pfizer and BioNTech of copying patented technology in the development of their COVID-19 vaccine.
FDA Plans to Approve Omicron-Targeting Booster Vaccines
Pfizer-BioNTech and Moderna have developed new booster shots optimized for Omicron. They could be approved as soon as Labor Day.
Moderna Files for Authorization for Its Bivalent COVID-19 Vaccine Booster
If granted the Emergency Use Authorization (EUA), this vaccine would be available for individuals 18 years and older.
Top 5 Infectious Disease Stories: Fauci’s Retirement and More
Read this week’s top infectious disease stories you may have missed, including Dr. Anthony Fauci’s announcement.
Pfizer-BioNTech File for Authorization for Bivalent Booster COVID-19 Vaccine
The companies are requesting the Emergency Use Authorization (EUA) for 30-µg booster dose of an Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for individuals 12 years of age and older.
Our Price for Not Aiming Higher: Long COVID Is Here to Stay
Guest author Seth Lederman, MD, calls Long COVID "one of the most pressing global health threats I have seen since fighting HIV/AIDS."
Third Dose of COVID-19 Vaccines May Boost Immunity in Patients with Hematologic Cancers
A third dose of mRNA COVID-19 vaccines may allow most immune compromised patients with hematologic cancers to achieve antibody response levels similar to those of healthy adults after a two-dose series.
Report Finds "Mix-and-Match" COVID-19 Booster Approach More Effective
People who initially received an mRNA vaccine but were boosted with the Janssen vaccine had superior immune responses, the study found.
How Many People Contract Omicron Without Knowing?
56% of adults with evidence of Omicron seropositivity did not know they were infected.
Risk Factors for “Long COVID” in Children
More symptoms, older age, and longer hospitalization time increased the risk of post-COVID-19 conditions (long COVID) in children.
2 Clarke Drive Cranbury, NJ 08512